The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
Open accessAbstract
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large‐cell lymphoma. Since then, ALK has been associated with other types of cancers, including non‐small‐cell lung cancer (NSCLC). More than 19 different ALK fusion partners have been discovered in NSCLC, including EML4, KIF5B, KLC1, and TPR. Most of these ALK fusions in NSCLC patients respond well to the ALK inhibitor, crizotinib. In this paper, we reviewed fusion partner genes with ALK, detection methods for ALK‐rearrangement (ALK‐R), and the ALK‐tyrosine kinase inhibitor, crizotinib, used in NSCLC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Global patterns of cancer incidence and mortality rates and trends
Jemal, A., Center, M. M., DeSantis, C., & Ward, E. M. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0437 · Cited by 2,778
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
Camidge, D. R., Bang, Y.-J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S.-H. I., Kim, D.-W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,268
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,189
Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H. G., Kim, J., Chiang, D., Thomas, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 993
Shaw, A. T., Yeap, B. Y., Solomon, B. J., Riely, G. J., Gainor, J., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S.-H. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 899
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2291 · Cited by 882
Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B., & Yamamoto, T. (1997) · Oncogene · doi:10.1038/sj.onc.1200849 · Cited by 726
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Hallberg, B., & Palmer, R. H. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3580 · Cited by 645
Kim, D.-W., Tiseo, M., Ahn, M.-J., Reckamp, K. L., Hansen, K. H., Kim, S.-W., Huber, R. M., West, H. L., Groen, H. J. M., Hochmair, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5904 · Cited by 581
Ou, S.-H. I., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C.-H., Hughes, B., Lena, H., Moro-Sibilot, D., Bearz, A., Ramirez, S. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 580
Shaw, A. T., Kim, T. M., Crinò, L., Gridelli, C., Kiura, K., Liu, G., Novello, S., Bearz, A., Gautschi, O., Mok, T., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30339-x · Cited by 567
A mouse model for EML4-ALK -positive lung cancer
Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805381105 · Cited by 512
Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., Okumura, S., Nakagawa, K., Soda, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815e8b60 · Cited by 467
ALK in Lung Cancer: Past, Present, and Future
Shaw, A. T., & Engelman, J. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5353 · Cited by 461
Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer
Choi, Y. L., Takeuchi, K., Soda, M., Inamura, K., Togashi, Y., Hatano, S., Enomoto, M., Hamada, T., Haruta, H., Watanabe, H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6158 · Cited by 438
Genomic alterations in lung adenocarcinoma
Devarakonda, S., Morgensztern, D., & Govindan, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00077-7 · Cited by 404
McDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 399
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J., Capelletti, M., Wang, L., Gray, N. S., Wilner, K., Christensen, J. G., Demetri, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 335
Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 335
Refining the treatment of NSCLC according to histological and molecular subtypes
Thomas, A., Liu, S. V., Subramaniam, D. S., & Giaccone, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.90 · Cited by 321
EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
Horn, L., & Pao, W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6661 · Cited by 319
Translocations involving anaplastic lymphoma kinase (ALK)
Duyster, J., Bai, R.-Y., & Morris, S. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204594 · Cited by 279
Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2683 · Cited by 274
Togashi, Y., Soda, M., Sakata, S., Sugawara, E., Hatano, S., Asaka, R., Nakajima, T., Mano, H., & Takeuchi, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031323 · Cited by 267
Treating ALK-positive lung cancer—early successes and future challenges
Camidge, D. R., & Doebele, R. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.43 · Cited by 236
Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer
Mano, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00972.x · Cited by 229
Ou, S.-H. I., Bartlett, C. H., Mino-Kenudson, M., Cui, J., & Iafrate, A. J. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0311 · Cited by 224
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
Thunnissen, E., Bubendorf, L., Dietel, M., Elmberger, G., Kerr, K., Lopez-Rios, F., Moch, H., Olszewski, W., Pauwels, P., Penault-Llorca, F., et al. (2012) · Virchows Archiv · doi:10.1007/s00428-012-1281-4 · Cited by 212
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Heuckmann, J. M., Hölzel, M., Sos, M. L., Heynck, S., Balke-Want, H., Koker, M., Peifer, M., Weiss, J., Lovly, C. M., Grütter, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1648 · Cited by 191
ALKoma: A Cancer Subtype with a Shared Target
Mano, H. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0009 · Cited by 182
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
(2011) · New England Journal of Medicine · doi:10.1056/nejmx110006 · Cited by 179
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Wu, J., Savooji, J., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0251-8 · Cited by 169
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
Motegi, A., Fujimoto, J., Kotani, M., Sakuraba, H., & Yamamoto, T. (2004) · Journal of Cell Science · doi:10.1242/jcs.01183 · Cited by 167
Yasuda, H., de Figueiredo-Pontes, L. L., Kobayashi, S., & Costa, D. B. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182570919 · Cited by 161
Cabillic, F., Gros, A., Dugay, F., Bégueret, H., Mesturoux, L., Chiforeanu, D. C., Dufrenot-Petitjean-Roget, L., Jauffret, V., Dachary, D., Corre, R., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000072 · Cited by 151
Anaplastic lymphoma kinase in human cancer
Barreca, A., Lasorsa, E., Riera, L., Machiorlatti, R., Piva, R., Ponzoni, M., Kwee, I., Bertoni, F., Piccaluga, P. P., Pileri, S. A., et al. (2011) · Journal of Molecular Endocrinology · doi:10.1530/jme-11-0004 · Cited by 140
Ying, J., Guo, L., Qiu, T., Shan, L., Ling, Y., Liu, X., & Lü, N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt295 · Cited by 128
Ali, S. M., Hensing, T. A., Schrock, A. B., Allen, J. M., Sanford, E. M., Gowen, K. A., Kulkarni, A., He, J., Suh, J. H., Lipson, D., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0497 · Cited by 128
ALK Status Testing in Non–Small Cell Lung Carcinoma
Minca, E. C., Portier, B. P., Wang, Z., Lanigan, C. P., Farver, C. F., Feng, Y., Ma, P. C., Arrossi, V., Pennell, N. A., & Tubbs, R. R. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.01.004 · Cited by 122
Miyake, I., Hakomori, Y., Shinohara, A., Gamou, T., Saito, M., Iwamatsu, A., & Sakai, R. (2002) · Oncogene · doi:10.1038/sj.onc.1205735 · Cited by 116
Novel ALK inhibitors in clinical use and development
Iragavarapu, C., Mustafa, M., Akinleye, A., Furqan, M., Mittal, V., Cang, S., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0122-8 · Cited by 99
Jung, Y., Kim, P., Jung, Y., Keum, J., Kim, S., Choi, Y. S., Do, I., Lee, J., Choi, S., Kim, S., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21945 · Cited by 95
HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib
Fang, D. D., Zhang, B., Gu, Q., Lira, M. E., Xu, Q., Sun, H., Qian, M., Sheng, W., Ozeck, M., Wang, Z., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000087 · Cited by 95
Toyokawa, G., & Seto, T. (2015) · Oncology Research and Treatment · doi:10.1159/000430852 · Cited by 93
Novel ALK fusion partners in lung cancer
Iyevleva, A. G., Раскин, Г. А., Tiurin, V. I., Соколенко, А. П., Mitiushkina, N. V., Алексахина, С. Н., Garifullina, A. R., Strelkova, T. N., Merkulov, V. O., Ivantsov, A. O., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.028 · Cited by 83
Noh, K., Lee, M., Lee, S. E., Song, J., Shin, H., Kim, Y. J., Oh, D. Y., Jung, K., Sung, M., Kim, M., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4950 · Cited by 77
Li, T., Maus, M. K. H., Desai, S. J., Beckett, L. A., Stephens, C. L., Huang, E., Hsiang, J., Zeger, G. D., Danenberg, K. D., Astrow, S. H., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000030 · Cited by 61
Wang, J., Cai, Y., Dong, Y., Nong, J., Zhou, L., Liu, G., Su, D., Li, X., Wu, S., Chen, X., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101551 · Cited by 59
Li, W., Zhang, J., Guo, L., Chuai, S., Shan, L., & Ying, J. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.145 · Cited by 54
Shan, L., Jiang, P., Xu, F., Zhang, W., Guo, L., Wu, J., Zeng, Y., Jiao, Y., & Ying, J. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000467 · Cited by 53
Mitiushkina, N. V., Iyevleva, A. G., Полторацкий, А. Н., Ivantsov, A. O., Togo, A. V., Polyakov, I. S., Орлов, С. В., Matsko, D. E., Новик, В. И., & Имянитов, Е. Н. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21281 · Cited by 51
Okamoto, I., Iwama, E., Harada, T., Takayama, K., & Nakanishi, Y. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s38868 · Cited by 48
Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas
Conde, E., Hernández, S., Prieto, M., Martínez, R., & López‐Ríos, F. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1172963 · Cited by 47
Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
Franco, R., Rocco, G., Marino, F. Z., Pirozzi, G., Normanno, N., Morabito, A., Sperlongano, P., Stiuso, P., Luce, A., Botti, G., et al. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.18 · Cited by 36
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
Mattsson, J. S. M., Brunnström, H., Jabs, V., Edlund, K., Jirström, K., Mindus, S., Fleur, L. L., Pontén, F., Karlsson, M. G., Karlsson, C., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2646-x · Cited by 35
ALK Inhibitors: What Is the Best Way to Treat Patients With ALK+ Non–Small-Cell Lung Cancer?
Toyokawa, G., & Seto, T. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.05.001 · Cited by 28
Hout, D. R., Schweitzer, B. L., Lawrence, K. D., Morris, S. W., Tucker, T., Mazzola, R., Skelton, R. L., McMahon, F. B., Handshoe, J., Lesperance, M., et al. (2017) · Cancers · doi:10.3390/cancers9080099 · Cited by 28
Wen, M., Wang, X., Sun, Y., Xia, J., Fan, L., Xing, H., Zhang, Z., & Li, X. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100303 · Cited by 23
Marchetti, A., Pace, M. V., Lorito, A. D., Canarecci, S., Felicioni, L., D’Antuono, T., Liberatore, M., Filice, G., Guetti, L., Mucilli, F., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.005 · Cited by 13
Weber, B., Liu, M., Sobkin, P., Morris, S. W., Hout, D. R., van der Westhuizen, N., Tonseth, R. P., & Saltman, D. L. (2015) · Journal of Medical Radiation Sciences · doi:10.1002/jmrs.144 · Cited by 8
Metadata
- Authors
- Du, X., Shao, Y., Qin, H., Tai, Y., & Gao, H.
- Venue
- Thoracic Cancer
- Publisher
- Wiley
- Published
- 2018-02-28
- Volume
- 9
- Issue
- 4
- Pages
- 423-430
- ISSN
- 1759-7706 (ISSN-L)
- 1759-7714
- OpenAlex
- W2791498761
- Cited by
- 275
- References
- 71
- FWCI
- 16.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.